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Introduction {#s0005}
============

Transcripts that are more than 200 nucleotides in length and lack the evident protein-coding potentiality are referred to as long non-coding RNAs (lncRNAs). lncRNAs not only contain functionally redundant sequences, but also exhibit low sequence conservation, which increases the complexity of their biological functions [@b0005]. lncRNAs exert their functions through diverse mechanisms, including interaction with genomic DNA, proteins, mRNA, and other categories of ncRNAs, consequently regulating gene expression at multiple levels [@b0010], [@b0015], [@b0020], [@b0025], [@b0030], [@b0035], [@b0040]. Recent studies have demonstrated that lncRNA-mediated regulation of gene expression is involved in embryogenesis, development, differentiation, and disease progression [@b0045], [@b0050], [@b0055]. Therefore, lncRNAs have been thought to participate in the construction of organismal regulatory network by adding different layers to control gene expression.

Enhancers are a set of DNA elements that were initially revealed to positively modulate the transcription of nearby genes in an orientation-independent manner [@b0060]. Subsequent studies further demonstrate that these elements possess the ability to orchestrate temporal and tissue-specific gene expression [@b0065], [@b0070]. Several effector models, such as "looping", "tracking", and "oozing", have been proposed to explain how enhancers exert their functions [@b0075]. While most findings appear to favor these models, the underlying molecular details remain largely unknown. Recently, a novel class of enhancer-transcribed ncRNAs, referred to as enhancer RNAs (eRNAs), have been uncovered [@b0080], [@b0085], [@b0090]. eRNAs are 0.5--5 kb in length and therefore arbitrarily classified into lncRNAs [@b0095]. The discovery of eRNAs, as well as their "emerging" ability to affect enhancer activity, has provided new insights into the enhancer action ([Table 1](#t0005){ref-type="table"}).Table 1**The main timeline of eRNA studiesYearBrief description and significanceRefs.**1990, 1992The early studies demonstrating that transcripts can be produced from enhancer regions[@b0100], [@b0105]  2010The first paper proposing the notion of eRNAs[@b0080]  2010, 2012Genome-wide analysis suggesting that enhancers may be generally transcribed[@b0085], [@b0090]  2013, 2014Increasing evidence showing that eRNAs play an important role in regulating gene transcription via diverse mechanisms[@b0110], [@b0115], [@b0120], [@b0125], [@b0130], [@b0135]  2014*In vivo* study confirming that many eRNAs are expressed in a tissue-specific manner[@b0140]  2014Study revealing a comprehensive transcriptomic profiling of eRNAs in humans[@b0145]  2015Study illuminating the role of RNA exosome in controlling eRNA degradation[@b0150]  2016Study showing that some eRNAs marked with m^5^C are responsible for metabolic stress[@b0155]  [^5]

Enhancer activity in gene regulation {#s0010}
====================================

Advances in genome-wide analysis technologies make it possible to investigate the chromatin features of enhancers. Using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq), it has been shown that enhancers with high activity usually display a low enrichment of H3K4me3, an epigenetic modification generally found at the promoter region of active genes [@b0160], [@b0165], [@b0170]. As a matter of fact, the activated enhancers are specifically marked by H3K27ac, whereas the poised enhancers are generally characterized by the absence of H3K27ac and the enrichment of H3K27me3 and/or H3K9me3 [@b0175]. A large number of enhancers with cell-type specificity have been found to share these epigenetic features [@b0175]. Furthermore, the status of the poised enhancers could be reversed when the epigenetic modification of H3K27me3 is replaced by H3K27ac [@b0175]. Interestingly, some transcription factors (TFs), including p300/CBP, are found to occupy the enhancer element, leading to an open chromatin conformation that confers high sensitivity of enhancers to DNase I [@b0180], [@b0185].

Some models, including "looping", "tracking", and "oozing", have been proposed to explain how enhancers function. In the "tracking" model, enhancer is proposed to diffuse in one dimension along the chromatin to seek a promoter [@b0190], whereas the "oozing" model presumes that a complex resides at the enhancer and then polymerizes alongside the chromatin bi-directionally until it hits a promoter [@b0190], [@b0195], [@b0200]. The predominant one, however, is the "looping" model, which involves the loop formation between the promoter and the enhancer [@b0205], [@b0210]. Thanks to chromosome conformation capture (3C) technology and its high-throughput derivatives, this model has been supported by several studies aiming to reveal chromatin architecture [@b0215], [@b0220], [@b0225], [@b0230]. In accordance with the "looping" model, some complexes associated with chromatin architecture formation have been identified. For instance, mediator and cohesin are reported to co-occupy the enhancer and promoter, thus guiding the formation of chromatin loop [@b0205], [@b0210].

Enhancers produce non-coding transcripts {#s0015}
========================================

In addition to TFs, RNA polymerase II (RNAPII) has also been found to be localized at many enhancers. In mouse cortical neurons, a large number of neuronal activity-controlled enhancers are recognized by the general transcriptional co-activator CREB binding protein (CBP). Upon KCl stimulation, CBP at enhancers recruits RNAPII and switches on the transcription [@b0080]. In lipopolysaccharide (LPS)-stimulated mouse macrophages, the occupancy profile of the enhancer-related chromatin signature H3K4me1 indicated that 70% of extragenic transcription sites overlap enhancer elements. Further analysis using qRT-PCR showed that 96 out of 100 RNAPII-binding enhancers examined produce detectable transcripts [@b0085]. Taken together, these studies provide strong evidence for the transcriptional potentiality of the enhancers.

Global nuclear run-on followed by high-throughput sequencing (GRO-seq) has been applied extensively to map nascent RNA across genome. Using this approach, it has been reported that enhancers recognized by androgen receptor (AR) are able to serve as transcription template to produce eRNAs during the reprogramming of hormonal response [@b0235]. In macrophages, Rev-Erbs (Rev-Erb-α and Rev-Erb-β) and Kdo2-lipid A (KLA)-stimulated toll-like receptor 4 (TLR4) are well-characterized nuclear receptors that operate through impacting the enhancer activity [@b0110], [@b0240]. A number of Rev-Erb-binding enhancers display the active chromatin features, namely, the presence of H3K4me1 and the absence of H3K4me3 [@b0110]. Additional GRO-seq-derived analysis has also shown that most of these enhancers undergo bidirectional transcription [@b0110]. In the case of TLR4-regulated enhancer activity, GRO-seq analysis reveals widespread enhancer transcription in mouse macrophages upon the treatment with the TLR4 agonist KLA [@b0245].

p53 is a core tumor suppressor that regulates the genes associated with cell proliferation and survival through recognizing and binding to the regulatory regions of transcription units [@b0250]. Many of the p53-binding genomic regions share the enhancer hallmarks and produce non-coding transcripts in a p53-dependent manner [@b0115]. Similarly, two independent groups have discovered that, in breast cancer cells, 17β-oestradiol (E2)-bound estrogen receptor α (ERα) binds to thousands of enhancers and causes enhancer transcription [@b0120], [@b0255]. In addition, activation of the transcription factor forkhead box O3 (FOXO3), which is associated with human longevity, has also been reported to potentiate production of non-coding transcripts from enhancers [@b0260].

The β-globin locus control region (LCR) regulates transcription of the globin genes 10--50 kb away during erythroid cell differentiation [@b0265]. Unexpectedly, the hypersensitive site 2 (HS2) enhancer in the β-globin LCR is found to undergo autonomous transcription in K562 cells, giving rise to several non-coding, intergenic RNAs [@b0270]. In murine T cell populations, 7 DNase I-hypersensitive sites (DHSs) have been identified in *IL-10*, a key gene involved in suppressing cell-mediated immunity and necessary for the development of several T-regulatory cell populations. Among them, 5 DHSs act as enhancers and are transcribed to produce intergenic RNAs upon stimulus [@b0275]. Differentiation of skeletal muscle is carried out by myogenic regulatory factors that include MyoD and MyoG [@b0280], [@b0285]. Interestingly, MyoD and MyoG occupy thousands of extragenic regions, which show enhancer features and are transcribed to produce non-coding transcripts [@b0125]. More recently, Pulakanti et al. have reported that, in mouse embryonic stem cells (ESCs), numerous enhancers linked to pluripotency-associated genes are transcribed [@b0290]. Collectively, the discovery of a large scale of non-coding transcripts named eRNAs indicates that enhancer transcription may be a common event in a variety of biological systems.

eRNAs share some properties with lncRNAs {#s0020}
========================================

Besides the length and protein-coding potentiality, many eRNAs share some other properties with lncRNAs. Like the polyadenylated lncRNAs, most eRNAs are transcribed by RNAPII and retained in the nucleus [@b0095]. In addition to the single-stranded form, some lncRNAs are found to exist as double-stranded molecules. A notable example is that Alu repeats are bidirectionally transcribed to facilitate formation of the RNA duplex [@b0295]. Similarly, while certain enhancers can be transcribed uni-directionally, transcription of RNAPII-controlled enhancers is usually bi-directional, emanating both the sense and antisense transcripts [@b0080], [@b0120] ([Figure 1](#f0005){ref-type="fig"}). Interestingly, it has been reported that many intragenic enhancers serve as alternative promoters to generate a set of spliced, multi-exonic, and polyadenylated RNAs, termed as meRNAs [@b0300]. Distinct from the eRNAs discussed above that are expressed at a low level, meRNAs are highly abundant in specific cell types. However, the detailed functions of these meRNAs await further interrogation.Figure 1**Distinct types of eRNAs**Uni-directional and polyadenylated eRNAs are shown in the upper part of the diagram, whereas bi-directional and non-polyadenylated eRNAs are shown in the lower part of the diagram. RNAPII, RNA polymerase II; TF, transcription factor.

Functionality of eRNAs and lncRNAs in enhancer activity {#s0025}
=======================================================

Functions of eRNAs have been associated with enhancer activity. eRNA production from p53-bound enhancer regions (p53BERs) is p53-dependent and required for the p53-dependent activation of gene expression [@b0115]. p53 activated by ionizing radiation induces eRNA production by increasing p53 binding to p53BERs. Moreover, although p53 is accumulated upon ionizing radiation, small interfering RNA (siRNA)-mediated knockdown of these eRNAs inhibits induction of the nearby p53 target genes [@b0115]. Similarly, depletion of the eRNAs arising from ERα-binding sites following estradiol (E2) stimulation results in diminished transcription of the neighboring genes in human breast cancer cells [@b0120].

Distinct from p53 and ERα, which induce eRNA transcription, the enhancer-binding nuclear receptor Rev-Erbs act conversely to inhibit enhancer transcription [@b0110]. The Rev-Erb-controlled eRNAs are also involved in regulating enhancer activity and expression of their neighboring genes [@b0110]. Given their specific expression profile in macrophage lineage, eRNAs may participate in the construction of the macrophage-specific gene regulatory network [@b0110].

In the myogenic gene regulatory network, the core enhancer (CE) and two distal regulatory regions (DRRs) of *myoD1* are transcribed to eRNAs, namely ^CE^RNA and ^DRR^RNA [@b0125]. After impeding the myogenic differentiation program, depletion of ^CE^RNA and ^DRR^RNA impairs the boost of *myoD* and *myoG* expression, respectively [@b0125]. The lncRNA *Evf-2* is derived from the enhancer of *Dlx-5/6* upon sonic hedgehog (Shh) induction, coincident with *Dlx-5* and *Dlx-6* activation [@b0305]. The enhancer activity is abolished upon *Evf-2* depletion, whereas enforced *Evf-2* expression promotes the enhancer activity, revealing the requirement of *Evf-2* for the enhancer activity. Taken together, these studies strongly point to eRNAs as the key players behind the DNA elements, enhancers, in regulation of gene transcription.

Like eRNAs, some lncRNAs derived from genomic regions other than enhancer also function in activating nearby gene via their "enhancer" function, which are named as eRNA-like lncRNAs. For example, *HOXA distal transcript antisense RNA* (*HOTTIP*), a long intergenic noncoding RNA (lincRNA) transcribed from the 5′ tip of the *HOXA* locus, is able to coordinate the activation of several 5′ *HOXA* genes in human anatomically distal cells [@b0310]. Similarly, the lncRNA *Nettoie Salmonella pas Theiler's* (NeST) is shown to exert enhancer-like function to activate the neighboring *interferon-γ* locus, thereby contributing to host susceptibility to microbial pathogens [@b0315]. Moreover, some other lncRNAs termed as ncRNA-activating (ncRNA-a) have been discovered in many cell types, and they also participate in the transcriptional activation of neighboring protein-coding genes [@b0320].

The mechanisms underlying eRNA action {#s0030}
=====================================

The eRNA-like lncRNAs exert transcription-promoting activity via diverse mechanisms. For example, ncRNA-a lncRNAs are proposed to work by facilitating long-range chromatin looping formation that alters chromosomal spatial structure [@b0320]. Similar to ncRNA-a lncRNAs, most eRNAs exert enhancer function by mediating formation of the local promoter--enhancer looping ([Figure 2](#f0010){ref-type="fig"}). Using an RNA tethering reporter assay, studies on the eRNAs involved in p53BER regulation reveal p53BER interaction with several distant protein-coding genes, which is necessary for the activation of these p53 target genes [@b0115]. Intriguingly, the long-range interactions between the promoter and enhancer are p53-independent, implying that eRNAs produced from p53BERs may act on pre-established chromatin conformations. Nevertheless, other factors involved in this process remain to be identified.Figure 2**Schematic model depicting how eRNAs work**The transcribed eRNAs interact with RNAPII and proteins (X), thus facilitating promoter--enhancer looping formation and then enhancing target gene transcription. RNAPII, RNA polymerase II; eRNA, enhancer RNA.

A more precise effector model for eRNAs has been proposed in a subsequent study by investigating roles of the E2-induced eRNAs in controlling the neighboring genes in MCF-7 cells [@b0120]. Consistent with the results from tethering reporter assay, eRNA depletion mediated by siRNA or locked nucleic acid antisense oligos (LNAs) leads to reduced transcription of the adjacent coding genes, indicating that eRNAs *per se* are necessity for induction of neighboring genes, but not by-products of enhancer activation. Despite lack of effect on the binding of ERα to enhancer elements, eRNA depletion leads to substantial alteration in the specific promoter--enhancer interactions. Moreover, it has been shown that cohesin is recruited to the interrogated enhancers upon E2 treatment [@b0325]. Notably, cohesin subunits can bind to eRNAs, and eRNA depletion decreases cohesion occupancy at enhancers, suggesting that eRNAs might act as "guiding" molecules to recruit the functional complexes. The E2-induced eRNA transcription has also been investigated in another study. Hah and colleagues indicate that eRNA repression caused by the transcriptional elongation inhibitor flavopiridol do not alter the specific promoter--enhancer interactions [@b0255]. This seems to be in contrast with the effect of siRNA- or LNA-mediated eRNA depletion described above. Given that flavopiridol also represses the expression of protein-coding genes, it is speculated that the initial synthesis of eRNAs may be sufficient for chromatin looping establishment [@b0330]. Therefore, eRNAs may guide gene activation in *cis* via recruiting chromatin modifiers and affecting chromosome conformation.

^CE^RNA and ^DRR^RNA derived from *myoD1* locus function through more complicated patterns [@b0125]. Depletion of ^CE^RNA, but not that of ^DRR^RNA, interferes with the expression of neighboring gene *myoD*, indicating that ^CE^RNA is directly associated with enhancer-mediated *myoD* activation and exerts regulatory effect in *cis*. Although ^DRR^RNA depletion has little impact on *myoD* expression, deletion of the DRR DNA element is shown to reduce *myoD* expression in all myogenic lineages [@b0335]. Consistent with the essential role of DRR in the early myogenic differentiation program, depletion of ^DRR^RNA abolishes the activation of myoD target genes (*e.g.*, *myoG* and *myh*) and hinders the myogenic differentiation program severely [@b0125]. Of critical importance, overexpression of the 1.2 kb and 2.0 kb fragments of ^DRR^RNA can activate *myoG* expression and the myogenic gene regulatory network but has little effect on *myoD* transcription, suggesting that ^DRR^RNA exerts its function of gene activation in *trans* and in a *myoD*-independent manner. Although these two eRNAs, ^CE^RNA and ^DRR^RNA, function in *cis* and in *trans*, respectively, further experiments demonstrate that both of them promote chromatin accessibility and RNAPII assembly at specific loci to activate the corresponding target genes. Another example of eRNA that act in *trans* is *Evf-2*, since its enhancer activity could be promoted by ectopic overexpression of full-length *Evf-2* or its 5′ fragment [@b0305]. Taken together, these studies reinforce the notion that eRNAs can act in *cis* or in *trans* to alter chromatin architecture.

It has also been reported that the process of enhancer transcription, in addition to the resultant eRNA transcripts, can mediate the enhancer activity. In the case of TLR4 induction, deposition of H3K4 methylation is established upon enhancer transcription [@b0245]. Inhibition of eRNA elongation is correlated with a reduction in the deposition of local H3K4me2. However, LNA-mediated eRNA depletion exhibits minimal effect on the H3K4me2 deposition. These data manifest that enhancer transcription, but not the eRNA molecule itself, is required for the H3K4me2 deposition. Similarly, another study also confirms that enhancer activation in AR reprogramming relies on the process of enhancer transcription, and the produced eRNAs might only serve as "signal" molecules to indicate the active status of enhancers [@b0235].

Perspectives {#s0035}
============

Enhancers were discovered about thirty years ago, and their "classic" functions in activating gene expression have been well documented. Discovery of enhancer transcription and the resultant eRNAs provides new insight into the enhancer functions. Moreover, several groups have identified a set of super-enhancers that comprise multiple transcriptional enhancers, and found that these super-enhancers are associated with cell differentiation and diseases [@b0340], [@b0345], [@b0350]. We are only beginning to understand the real realm of eRNAs. While several effector models have been proposed to explain how eRNAs exert their functions, the detailed molecular mechanisms through which enhancers become activated as transcription units remain largely mysterious. For example, what is the mechanism underlying expression and regulation of eRNAs? Is the transcription apparatus on enhancers identical to that on promoters? What are the *cis*-acting elements and *trans*-acting factors that determine the initiation, elongation, and termination of eRNA transcription? Enhancer aberration and eRNA-mediated gene activation have been implicated in diseases that include breast cancer [@b0115], [@b0120], [@b0255]. Therefore, studies on the emerging eRNAs, especially their expression regulation, may provide new strategies for the therapy of diseases.
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